ECYT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ECYT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
The historical rank and industry rank for Endocyte's Beneish M-Score or its related term are showing as below:
During the past 10 years, the highest Beneish M-Score of Endocyte was 0.00. The lowest was 0.00. And the median was 0.00.
The historical data trend for Endocyte's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Endocyte Annual Data | |||||||||||||||||||||
Trend | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | |||||||||||
Beneish M-Score | Get a 7-Day Free Trial | -0.83 | -0.46 | -115.57 | -3.10 | -3.04 |
Endocyte Quarterly Data | ||||||||||||||||||||
Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | |
Beneish M-Score | Get a 7-Day Free Trial | -3.86 | -3.04 | -0.86 | 73.23 | 45.54 |
For the Biotechnology subindustry, Endocyte's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Endocyte's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Endocyte's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Endocyte for today is based on a combination of the following eight different indices:
M | = | -4.84 | + | 0.92 * DSRI | + | 0.528 * GMI | + | 0.404 * AQI | + | 0.892 * SGI | + | 0.115 * DEPI |
= | -4.84 | + | 0.92 * 0.9568 | + | 0.528 * 1 | + | 0.404 * 117.4821 | + | 0.892 * 1.7917 | + | 0.115 * 0.805 | |
- | 0.172 * SGAI | + | 4.679 * TATA | - | 0.327 * LVGI | |||||||
- | 0.172 * 0.7172 | + | 4.679 * 0.044403 | - | 0.327 * 0.5311 | |||||||
= | 45.63 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Sep18) TTM: | Last Year (Sep17) TTM: |
Total Receivables was $0.05 Mil. Revenue was 0.086 + 0.014 + 0.016 + 0.013 = $0.13 Mil. Gross Profit was 0.086 + 0.014 + 0.016 + 0.013 = $0.13 Mil. Total Current Assets was $351.31 Mil. Total Assets was $355.20 Mil. Property, Plant and Equipment(Net PPE) was $1.56 Mil. Depreciation, Depletion and Amortization(DDA) was $0.82 Mil. Selling, General, & Admin. Expense(SGA) was $16.91 Mil. Total Current Liabilities was $7.68 Mil. Long-Term Debt & Capital Lease Obligation was $0.00 Mil. Net Income was -12.608 + -11.565 + -8.603 + -8.564 = $-41.34 Mil. Non Operating Income was -0.008 + -0.043 + 0.001 + -16.529 = $-16.58 Mil. Cash Flow from Operations was -15.528 + -11.054 + -7.705 + -6.246 = $-40.53 Mil. |
Total Receivables was $0.03 Mil. Revenue was 0.033 + 0.013 + 0.013 + 0.013 = $0.07 Mil. Gross Profit was 0.033 + 0.013 + 0.013 + 0.013 = $0.07 Mil. Total Current Assets was $104.39 Mil. Total Assets was $106.85 Mil. Property, Plant and Equipment(Net PPE) was $2.45 Mil. Depreciation, Depletion and Amortization(DDA) was $0.94 Mil. Selling, General, & Admin. Expense(SGA) was $13.16 Mil. Total Current Liabilities was $4.35 Mil. Long-Term Debt & Capital Lease Obligation was $0.00 Mil. |
1. DSRI = Days Sales in Receivables Index
Measured as the ratio of Revenue in Total Receivables in year t to year t-1.
A large increase in DSR could be indicative of revenue inflation.
DSRI | = | (Receivables_t / Revenue_t) | / | (Receivables_t-1 / Revenue_t-1) |
= | (0.048 / 0.129) | / | (0.028 / 0.072) | |
= | 0.372093 | / | 0.388889 | |
= | 0.9568 |
2. GMI = Gross Margin Index
Measured as the ratio of gross margin in year t-1 to gross margin in year t.
Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.
GMI | = | GrossMargin_t-1 | / | GrossMargin_t |
= | (GrossProfit_t-1 / Revenue_t-1) | / | (GrossProfit_t / Revenue_t) | |
= | (0.072 / 0.072) | / | (0.129 / 0.129) | |
= | 1 | / | 1 | |
= | 1 |
3. AQI = Asset Quality Index
AQI is the ratio of asset quality in year t to year t-1.
Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.
AQI | = | (1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) | / | (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1) |
= | (1 - (351.311 + 1.556) / 355.204) | / | (1 - (104.393 + 2.446) / 106.845) | |
= | 0.006579 | / | 5.6E-5 | |
= | 117.4821 |
4. SGI = Sales Growth Index
Ratio of Revenue in year t to sales in year t-1.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
SGI | = | Sales_t | / | Sales_t-1 |
= | Revenue_t | / | Revenue_t-1 | |
= | 0.129 | / | 0.072 | |
= | 1.7917 |
5. DEPI = Depreciation Index
Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI | = | (Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) | / | (Depreciation_t / (Depreciaton_t + PPE_t)) |
= | (0.941 / (0.941 + 2.446)) | / | (0.82 / (0.82 + 1.556)) | |
= | 0.277827 | / | 0.345118 | |
= | 0.805 |
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.
SGA expenses index > 1 means that the company is becoming less efficient in generate sales.
SGAI | = | (SGA_t / Sales_t) | / | (SGA_t-1 /Sales_t-1) |
= | (16.907 / 0.129) | / | (13.158 / 0.072) | |
= | 131.062016 | / | 182.75 | |
= | 0.7172 |
7. LVGI = Leverage Index
The ratio of total debt to Total Assets in year t relative to yeat t-1.
An LVGI > 1 indicates an increase in leverage
LVGI | = | ((LTD_t + CurrentLiabilities_t) / TotalAssets_t) | / | ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1) |
= | ((0 + 7.675) / 355.204) | / | ((0 + 4.347) / 106.845) | |
= | 0.021607 | / | 0.040685 | |
= | 0.5311 |
8. TATA = Total Accruals to Total Assets
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA | = | (IncomefromContinuingOperations_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
= | (NetIncome_t - NonOperatingIncome_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t | |
= | (-41.34 - -16.579 | - | -40.533) | / | 355.204 | |
= | 0.044403 |
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Endocyte has a M-score of 45.63 signals that the company is likely to be a manipulator.
Thank you for viewing the detailed overview of Endocyte's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Patrick Machado | director | 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107 |
John C Aplin | director | ONE AMERICAN SQUARE STE 2850, INDIANAPOLIS IN 46282 |
David R. Mcavoy | officer: General Counsel | C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906 |
Alison A. Armour | officer: Chief Medical Officer | C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906 |
Dawn Svoronos | director | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Marc D Kozin | director | |
Michael T. Andriole | officer: Chief Financial Officer | C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906 |
Lesley Russell | director | 41 MOORES RD., FRAZER PA 19355 |
Beth Taylor | officer: VP Finance & Chief Acctg Off | 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906 |
Michael A. Sherman | director, officer: President and CEO | 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906 |
Fred A Middleton | director | 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708 |
Peter D Meldrum | director | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Ann Hanham | director | ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111 |
Chandra D Lovejoy | officer: VP of Regulatory Affairs | C/O PRONAI THERAPEUTICS, INC. 2150 - 885 WEST GEORGIA ST VANCOUVER A1 V6C 3E8 |
David D. Meek | officer: Chief Commercial Officer | 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906 |
From GuruFocus
By Marketwired Marketwired • 10-03-2018
By Marketwired Marketwired • 06-22-2018
By Marketwired Marketwired • 12-20-2018
By Marketwired Marketwired • 05-17-2018
By GlobeNewswire GlobeNewswire • 08-28-2018
By Marketwired Marketwired • 06-05-2018
By Marketwired Marketwired • 09-10-2018
By Marketwired Marketwired • 07-09-2018
By Marketwired Marketwired • 06-25-2018
By Marketwired Marketwired • 08-29-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.